


Monatepil maleate

Cat. No.:	HY-106818A
CAS No.:	103379-03-9
Molecular Formula:	C ₃₂ H ₃₄ FN ₃ O ₅ S
Molecular Weight:	591.69
Target:	Acyltransferase; Calcium Channel
Pathway:	Metabolic Enzyme/Protease; Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Monatepil maleate (AJ-2615) is a potent and orally active Ca ²⁺ -channel antagonist and a noncompetitive ACAT inhibitor. Monatepil maleate decreases blood pressure and improves plasma lipid metabolism. Monatepil maleate has the potential for the research of hyperlipidemia ^{[1][2]} .																
In Vivo	<p>Monatepil maleate (30 mg/kg; p.o.; once daily for 9 weeks) improves plasma lipid metabolism^[1].</p> <p>Monatepil maleate (30 mg/kg; p.o.; once daily for 6 weeks) inhibits ACAT activity and esterifies cholesterol content in high cholesterol diet monkeys^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>8 weeks, Male Japanese white rabbits (high cholesterol diet-fed)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o.; once daily for 9 weeks</td> </tr> <tr> <td>Result:</td> <td>Improved plasma lipid metabolism and reduced atherosclerotic lesions, decreased blood pressure.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>4-7 kg, 4-7 years monkeys (high cholesterol diet for 6 months)^[2]</td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o.; once daily for 6 weeks</td> </tr> <tr> <td>Result:</td> <td>Inhibited the increases of ACAT activity and esterified cholesterol content.</td> </tr> </table>	Animal Model:	8 weeks, Male Japanese white rabbits (high cholesterol diet-fed) ^[1]	Dosage:	30 mg/kg	Administration:	P.o.; once daily for 9 weeks	Result:	Improved plasma lipid metabolism and reduced atherosclerotic lesions, decreased blood pressure.	Animal Model:	4-7 kg, 4-7 years monkeys (high cholesterol diet for 6 months) ^[2]	Dosage:	30 mg/kg	Administration:	P.o.; once daily for 6 weeks	Result:	Inhibited the increases of ACAT activity and esterified cholesterol content.
Animal Model:	8 weeks, Male Japanese white rabbits (high cholesterol diet-fed) ^[1]																
Dosage:	30 mg/kg																
Administration:	P.o.; once daily for 9 weeks																
Result:	Improved plasma lipid metabolism and reduced atherosclerotic lesions, decreased blood pressure.																
Animal Model:	4-7 kg, 4-7 years monkeys (high cholesterol diet for 6 months) ^[2]																
Dosage:	30 mg/kg																
Administration:	P.o.; once daily for 6 weeks																
Result:	Inhibited the increases of ACAT activity and esterified cholesterol content.																

REFERENCES

[1]. Ikano A, et al. Effects of monatepil maleate, a new Ca²⁺ channel antagonist with alpha1-adrenoceptor antagonistic activity, on cholesterol absorption and catabolism in high cholesterol diet-fed rabbits. *Jpn J Pharmacol.* 1998 Nov;78(3):303-12.

[2]. Sumiya T, et al. Inhibitory effect of monatepil maleate on acyl-CoA:cholesterol acyltransferase activity in the liver of cholesterol-fed Japanese monkeys. *Am J*

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA